Drug intelligence / Profile preview

18F-LY3950321

Development stage: Phase 1
Lead developer: Avid Radiopharmaceuticals
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

18F-LY3950321 (also known as 18F-MNI-1256) is a radiolabeled positron emission tomography (PET) tracer developed for use as a diagnostic radiopharmaceutical. It targets granzyme B, an enzyme involved in immune cell-mediated cytotoxicity, and is used to enhance PET imaging by acting as a **granzyme B modulator**. The primary goal of its development has been to evaluate its safety, tolerability, and radiation dosimetry in healthy subjects. The drug was developed by Avid Radiopharmaceuticals and has reached early Phase 1 clinical trials focused on biodistribution and safety assessment in healthy volunteers[1][2][3][4][5].

Other names: 18F-MNI-1256

Targets

GZMB (Granzyme B)

Beyond the preview

Go deeper on 18F-LY3950321.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 18F-LY3950321.

Explore the full profile